Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2004 Jun;48(6):2331-3.
doi: 10.1128/AAC.48.6.2331-2333.2004.

ELVIRA HSV, a yield reduction assay for rapid herpes simplex virus susceptibility testing

Ruzena Stránská  1 , Rob Schuurman, David R Scholl, Joseph A Jollick, Carl J Shaw, Caroline Loef, Merjo Polman, Anton M van Loon
Affiliations

ELVIRA HSV, a yield reduction assay for rapid herpes simplex virus susceptibility testing

Ruzena Stránská et al. Antimicrob Agents Chemother. 2004 Jun.

Abstract

A colorimetric yield reduction assay, ELVIRA (enzyme-linked virus inhibitor reporter assay) HSV, was developed to determine the antiviral drug susceptibilities of herpes simplex virus (HSV). It uses an HSV-inducible reporter cell line. This simple and rapid assay has an objective readout, low inoculum size, and good reproducibility. The results correlate well with those of the plaque reduction assay.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Schematic overview of ELVIRA HSV procedure. RT, room temperature; OD, optical density.
FIG. 2.
FIG. 2.
The effect of duration of infection of HFF cells on sensitivity of ELVIRA HSV. HFF cell monolayers were infected with a range of HSV-1 inocula; and ELVIRA reporter cells were added after 12, 16, 20, and 24 h. Results are representative of four independent experiments performed in triplicate with HSV-1; error bars indicate SDs. OD, optical density.
FIG. 3.
FIG. 3.
Susceptibilities to ACV and PFA of well-characterized HSV strains and clinical isolates and clinical isolates from untreated patients determined by ELVIRA HSV (the results represent data combined from Table 1 and the Results).
See this image and copyright information in PMC

References

    1. Chen, Y., C. Scieux, V. Garrait, G. Socie, V. Rocha, J. M. Molina, D. Thouvenot, F. Morfin, L. Hocqueloux, L. Garderet, H. Esperou, F. Selimi, A. Devergie, G. Leleu, M. Aymard, F. Morinet, E. Gluckman, and P. Ribaud. 2001. Resistant herpes simplex virus type 1 infection: an emerging concern after allogeneic stem cell transplantation. Clin. Infect. Dis. 31:927-935. - PubMed
    1. Christophers, J., J. Clayton, J. Craske, R. Ward, P. Collins, M. Trowbridge, and G. Darby. 1998. Survey of resistance of herpes simplex virus to acyclovir in northwest England. Antimicrob. Agents Chemother. 42:868-872. - PMC - PubMed
    1. Danve-Szatanek, C., M. Aymard, D. Thouvenot, F. Morfin, G. Agius, I. Bertin, S. Billaudel, B. Chanzy, M. Coste-Burel, L. Finkielsztejn, H. Fleury, T. Hadou, C. Henquell, H. Lafeuille, M. E. Lafon, A. Le Faou, M. C. Legrand, L. Maille, C. Mengelle, P. Morand, F. Morinet, E. Nicand, S. Omar, B. Picard, B. Pozzetto, J. Puel, D. Raoult, C. Scieux, M. Segondy, J. M. Seigneurin, R. Teyssou, and C. Zandotti. 2004. Surveillance network for herpes simplex virus resistance to antiviral drugs: 3-year follow-up. J. Clin. Microbiol. 42:242-249. - PMC - PubMed
    1. Morfin, F., and D. Thouvenot. 2003. Herpes simplex virus resistance to antiviral drugs. J. Clin. Virol. 26:29-37. - PubMed
    1. Safrin, S., T. Elbeik, L. Phan, D. Robinson, J. Rush, A. Elbaggari, and J. Mills. 1994. Correlation between response to acyclovir and foscarnet therapy and in vitro susceptibility result for isolates of herpes simplex virus from human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 38:1246-1250. - PMC - PubMed

LinkOut - more resources